ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) CFO Mark C. Schneyer sold 5,434 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Wednesday, March 27th. The stock was sold at an average price of $17.90, for a total value of $97,268.60. Following the completion of the sale, the chief financial officer now owns 26,183 shares in the company, valued at $468,675.70. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
ACADIA Pharmaceuticals Price Performance
ACADIA Pharmaceuticals stock opened at $18.20 on Thursday. ACADIA Pharmaceuticals Inc. has a 1 year low of $17.56 and a 1 year high of $33.99. The company’s 50 day simple moving average is $23.85 and its 200-day simple moving average is $24.48.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative return on equity of 15.67% and a negative net margin of 8.44%. The company had revenue of $231.04 million for the quarter, compared to analysts’ expectations of $223.79 million. During the same quarter last year, the company earned ($0.26) EPS. ACADIA Pharmaceuticals’s revenue for the quarter was up 69.3% compared to the same quarter last year. Analysts predict that ACADIA Pharmaceuticals Inc. will post 0.64 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
A number of analysts have commented on the company. HC Wainwright reissued a “buy” rating and issued a $33.00 target price on shares of ACADIA Pharmaceuticals in a report on Wednesday, February 28th. Robert W. Baird started coverage on shares of ACADIA Pharmaceuticals in a research note on Tuesday, January 30th. They set an “outperform” rating and a $40.00 target price on the stock. Morgan Stanley decreased their target price on ACADIA Pharmaceuticals from $40.00 to $30.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 13th. StockNews.com raised shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, January 30th. Finally, JMP Securities reiterated a “market outperform” rating and set a $42.00 target price on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, ACADIA Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $36.12.
View Our Latest Report on ACAD
About ACADIA Pharmaceuticals
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Featured Articles
- Five stocks we like better than ACADIA Pharmaceuticals
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- Why Invest in 5G? How to Invest in 5G Stocks
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.